Pros and Cons in Radiation Oncology: A Technological Perspective
By L Mula-Hussain | BC Cancer Centre for the North – Prince George; BC – Canada | Faculty of Medicine – University of British Columbia; BC – Canada
Radiation oncology has undergone one of the most remarkable technological transformations in modern medicine. Since the discovery of X-rays by Wilhelm Conrad Röntgen in 1895, radiation therapy has evolved from rudimentary skin irradiation to highly sophisticated, image-guided, biologically adaptive, and precision-based cancer treatment. Over the past 130 years, technological innovation has continuously reshaped the field, improving tumor control, minimizing toxicity, and expanding the therapeutic possibilities for millions of patients worldwide. Yet, each technological advance has also introduced new complexities, ethical concerns, and disparities in access. The history of radiation oncology is therefore not only a story of scientific triumph, but also one of ongoing challenges in balancing innovation, safety, cost, and equity [1,2].
The origins of radiation oncology began almost immediately after Röntgen’s discovery of X-rays in 1895. Within months, physicians recognized that ionizing radiation could induce tissue damage and potentially treat tumors. Early practitioners used primitive X-ray tubes without adequate dosimetry or radiation protection, leading to unpredictable outcomes and significant complications. Initial enthusiasm was tempered by severe radiation injuries among both patients and clinicians, illustrating the dangers of applying new technologies without a full understanding of radiobiology and safety principles [3].
The discovery of radium by Marie Curie and Pierre Curie in 1898 introduced brachytherapy, allowing radiation sources to be placed directly within or near tumors. This represented one of the earliest examples of conformal treatment delivery. Radium therapy proved especially valuable for gynecological cancers and marked the beginning of targeted radiation approaches. However, the lack of standardized dosing and limited understanding of long-term radiation effects created substantial risks for both patients and healthcare workers [4].
By the mid-20th century, the development of megavoltage therapy revolutionized radiation oncology. The introduction of cobalt-60 machines in the 1950s enabled deeper tumor penetration while sparing superficial tissues. These machines became the backbone of radiotherapy worldwide and dramatically expanded the range of treatable cancers. Cobalt therapy represented a major technological leap because it offered more reliable dose delivery and improved treatment effectiveness compared with earlier orthovoltage systems [5].
Nevertheless, cobalt machines also revealed the limitations of technology-dependent oncology. Concerns about radioactive waste and radiation security surfaced, maintenance costs were high, and radioactive source degradation necessitated frequent replacement. In addition, treatment planning during this era remained largely two-dimensional, relying on plain radiographs and anatomical estimation rather than precise imaging.
Ultimately, the technological history of radiation oncology reflects both the extraordinary power and the inherent complexity of modern medicine.
The development of medical linear accelerators (LINACs) in the 1960s and 1970s transformed the field yet again. LINACs generate high-energy X-rays electronically without the need for radioactive isotopes, allowing safer and more flexible treatment delivery. Combined with the advent of computerized tomography (CT), radiation oncology entered the era of three-dimensional conformal radiotherapy (3D-CRT). Tumors could now be visualized in three dimensions, enabling improved dose shaping and better sparing of normal tissues [6].
One of the biggest advantages of contemporary radiation oncology was the technological integration of imaging and treatment planning. Computerized treatment planning systems improved precision, reproducibility, and quality assurance. However, these advances also increased dependence on sophisticated infrastructure, multidisciplinary expertise, and extensive quality control procedures. The complexity of modern radiotherapy systems introduced new opportunities for human error, software malfunction, and workflow failures.
The late 1990s and early 2000s witnessed the emergence of intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT). These technologies enabled highly conformal dose distributions that could escalate tumor dose while minimizing exposure to surrounding organs. Image guidance allowed clinicians to account for daily anatomical variation and organ motion, significantly improving treatment accuracy [7].
From a technological perspective, these innovations represented a paradigm shift toward precision oncology. Diseases once considered unsuitable for radiation due to proximity to critical organs became treatable with curative intent. SBRT transformed management strategies for early-stage lung cancer, oligometastatic disease, and spinal tumors. Radiosurgery provided non-invasive alternatives for brain lesions and vascular malformations [8].
Yet, increasing sophistication also brought unintended consequences. Modern radiation oncology became heavily reliant on advanced imaging, computing systems, and automation. Treatment planning evolved into a highly labor-intensive process involving radiation oncologists, medical physicists, dosimetrists, therapists, and information technology specialists. Financial costs escalated dramatically, contributing to inequalities between high-income and low-income healthcare systems. Many developing regions still depend on cobalt therapy because advanced LINAC-based technologies remain economically inaccessible [9].
Particle therapy, particularly proton therapy, represents another milestone in the technological evolution of radiation oncology. Proposed by Robert R. Wilson in 1946, proton therapy exploits the Bragg peak phenomenon, allowing radiation dose deposition directly within the tumor while minimizing exit dose. The advantages of proton therapy are especially relevant in pediatric malignancies and tumors near critical structures. Reduced integral dose may lower the risk of secondary malignancies and long-term toxicity. However, proton therapy centers require enormous financial investment, complex engineering infrastructure, and specialized expertise. Debate continues regarding cost-effectiveness and whether clinical outcomes consistently justify the expense for all tumor types [10].
In recent years, radiation oncology has entered the digital and biologically adaptive era. Artificial intelligence (AI), radiomics, adaptive radiotherapy, MRI-guided LINACs, and FLASH radiotherapy are redefining the future of the specialty. AI-based contouring and planning systems have the potential to improve efficiency, reduce interobserver variability, and personalize treatment. MRI-guided systems enable real-time visualization of soft tissue anatomy during irradiation, allowing adaptive treatment based on daily anatomical changes.
FLASH radiotherapy, characterized by ultra-high dose-rate radiation delivery, may represent one of the most promising breakthroughs of the 21st century. Early studies suggest that FLASH can spare normal tissues while maintaining tumor control, potentially improving the therapeutic ratio dramatically [11].
Despite these exciting developments, important concerns remain. AI-driven systems raise questions regarding transparency, accountability, and clinician oversight. Increasing automation may reduce opportunities for human verification. Rapid technological advancement also runs the risk of putting costly innovation ahead of public health fairness and global accessibility.
Looking back from 1895 to 2025, radiation oncology exemplifies how technology can continuously redefine medical practice. Each generation of innovation has improved precision, safety, and efficacy, enabling radiation therapy to remain a cornerstone of cancer management. However, technological advancement alone does not guarantee optimal patient care. The future success of radiation oncology will depend not only on innovation, but also on responsible implementation, equitable access, rigorous quality assurance, and continued emphasis on patient-centered care.
Ultimately, the technological history of radiation oncology reflects both the extraordinary power and the inherent complexity of modern medicine. The challenge for the next century will be ensuring that innovation serves not merely technological progress, but the broader goal of improving human health and reducing the global burden of cancer.
References
1. Del Regato JA. Radiological physicists in the history of radiotherapy. Phys Today. 1993;46(7):24-30.
2. Joiner M, van der Kogel A. Basic Clinical Radiobiology. 5th ed. Boca Raton: CRC Press; 2018.
3. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 8th ed. Philadelphia: Wolters Kluwer; 2019.
4. Perez CA, Brady LW. Principles and Practice of Radiation Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
5. Khan FM, Gibbons JP. Khan’s The Physics of Radiation Therapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
6. Thariat J, Hannoun-Levi JM, Sun Myint A, Vuong T, Gerard JP. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. 2013;10(1):52-60.
7. Bortfeld T. IMRT: a review and preview. Phys Med Biol. 2006;51(13):R363-R379.
8. Khan AMH, Hashmi SFA, Li B, Shaukat F, Ahmed Y, Alfishawy M, et al. Stereotactic radiotherapy: An educational narrative review. Prec Radiat Oncol. 2024;8(1):47-58. doi:10.1002/pro6.1222.
9. Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015;16(10):1153-1186.
10. Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7(1):37-43.
11. Bourhis J, Montay-Gruel P, Goncalves Jorge P, Bailat C, Petit B, Ollivier J, et al. Clinical translation of FLASH radiotherapy: Why and how? Radiother Oncol. 2019;139:11-17.